Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
about
Molecular mechanisms in multiple myeloma drug resistanceDrugging the unfolded protein response in acute leukemiasNew criteria for response assessment: role of minimal residual disease in multiple myelomaTargeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe myeloma stem cell concept, revisited: from phenomenology to operational termsNovel therapeutic strategies for multiple myelomaA novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceUtilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myelomaHumoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin UsersTumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in CancerHematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Differentiation stage of myeloma plasma cells: biological and clinical significance.SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Implications of heterogeneity in multiple myeloma.The generation of antibody-secreting plasma cells.Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.NEK2 mediates ALDH1A1-dependent drug resistance in multiple myelomaEffectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.Pathogenesis beyond the cancer clone(s) in multiple myeloma.The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaLongitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaLower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response
P2860
Q26776386-419ED304-9AC4-478E-A447-FFFFF3EBF6A9Q26801114-DD8196CE-8E8F-448E-8EDD-6672EDE43532Q27027512-7707E6A5-0FD7-47CF-ABE3-6273C939D2A5Q27314737-94A4A680-000C-4D29-B21E-8DB0ACB55201Q27692033-C8F8548F-5629-4B76-A405-8AEA89F5BF7CQ28075927-CDCDE46C-CB82-4B2A-BCA6-1A42FF7812B5Q28076070-B8C7D056-ADB3-4B43-8776-FD198457C6B2Q28081590-DACAFB9B-C51D-4D04-A22C-0B9F45C8B9E4Q28395203-38129B91-0070-4809-B109-C5E2C3EBA331Q28544663-49B1D066-7EA5-4317-A411-EAC10B0B1A63Q28552355-7DEE3831-A2F1-46FC-84B4-61209E426E2BQ29248711-42D9DE62-A9E1-4351-A48F-1E6BCDED681BQ33415584-F6E48F48-F025-46BA-9C1F-6C99EA404993Q33427510-4CDC896D-26AC-4E72-8DDA-EABB64B8FEBEQ33556178-D6802417-82C0-41EF-BCCB-69DC9E2488DFQ33694514-C1C2FD88-1AF5-4CCC-A314-F7F2D6D5FA4CQ33712516-41685F0D-9EB9-4B3A-BB0C-AAAD17D6E4E2Q33738889-E3327F9D-016E-473A-A97C-A92A6169DEB1Q33742779-752DBF77-9412-4AC4-BED8-3BFBE07A3B8BQ33914824-85F084AF-DD17-4EDA-82BB-161F2D41FFC8Q34463732-A6384AE9-CC08-4F1F-B96A-1F259A399B84Q34701285-3E06BE5B-8454-45A2-AB3D-5F81B78F78FAQ34788381-D2FF31B8-6297-4070-83B9-D459BF82FD70Q35067960-3A68F299-9237-45F3-A641-5FF017916969Q35104606-85DC42F1-1F37-46E8-9391-B34219F90E0FQ35178969-A6500650-5F5C-4C68-9677-CFAEB263E261Q35408665-4343464A-870C-4412-BAA5-6A18B4006081Q35550181-4C9A3958-9C85-44E1-BD44-D18AFEDF9D0FQ35590396-733AB6EC-82B0-4016-A735-0868485C156DQ35607266-7E6A0214-C8FE-4C28-9765-9AE513AAE29CQ35889653-128365A4-D61E-4EB9-AC74-C8463AD61698Q35932154-A2E7F9E3-C16D-416F-9F61-558D42BFC473Q36115692-E7FCEE74-7283-461C-B66D-1574274E31B3Q36146344-F415B69A-B902-4776-8623-6FAB01E951E9Q36284584-8035016A-24E3-4844-921E-9ED0BAF58D39Q36306807-26BEB188-3FD1-4E1E-A777-1440AB2EF84AQ36404060-71F59653-1A5A-426A-B991-073D539F5B1BQ36444233-696301F9-8506-4F8F-A49C-610E733F7627Q36526514-FA1CBE7F-A092-44BE-AA3F-68C8C5060E76Q36591114-D12BAC11-5932-4519-9FE3-F380F20ACA3B
P2860
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@en
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@nl
type
label
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@en
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@nl
prefLabel
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@en
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@nl
P2093
P2860
P1433
P1476
Xbp1s-negative tumor B cells a ...... esistance in multiple myeloma.
@en
P2093
A Keith Stewart
Chungyee Leung-Hagesteijn
Donna E Reece
Grace Cheung
Kim Chan Chung
Natalie Erdmann
P2860
P304
P356
10.1016/J.CCR.2013.08.009
P577
2013-09-01T00:00:00Z